Drugmakers Dispute Scope of Orphan Drug Exclusivity

International Pharmaceutical Regulatory Monitor
A A
Drugmakers argued against broad orphan exclusivity for Eagle Pharmaceuticals’ Bendeka (bendamustine) in public comments to the FDA.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00